NCT02759406已完成不适用
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
Palmaz Scientific0 个研究点目标入组 48 人开始时间: 2013年9月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 主要终点
- total percentage of strut coverage by Optical Coherence Tomography analysis
研究概览
简要总结
This is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent System.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients of any race greater than or equal to 18 years and of legal consent
- •Patients must be willing to comply with the specified follow-up evaluation schedule
- •Patients who sign an informed consent (signed and dated) prior to any study-related evaluation or procedure.
- •Patients who are willing to undergo a follow-up coronary angiogram and Endovascular Imaging via Optical Coherence Tomography
- •Patients willing to be maintained on Aspirin and Clopidogrel bisulfate (Plavix) for ninety (90) days post procedure.
- •Patients with a de novo coronary lesion causing angina and/or a positive function test
- •Patients who are eligible for percutaneous coronary interventions
- •Low risk NSTEMI defined as patients with ACS, unstable angina, positive cardiac biomarkers and hemodynamically stable as assessed by the Investigator.
- •Patients with an acceptable risk for coronary bypass graft surgery (CABG)
- •Intra-Procedure Angiographic Criteria:
- •Single de novo target lesion >50% diameter stenosis by angiography
- •Single target vessel 2.75 to 3.25 mm diameter
- •Lesion length of 14 to 20mm which is suitable for Palmaz Mach-5 Grooved Coronary Stent System or the Palmaz Bare Metal Coronary Stent System.
排除标准
- •Known allergy or sensitivity to cobalt chromium (CoCr) alloy or its components.
- •Known sensitivity or allergy to aspirin, radiographic contract agents (that cannot be pre-treated adequately).
- •Patients unable to tolerate anticoagulant therapy or antiplatelet therapy.
- •History of bleeding or known coagulopathy.
- •Patients with thrombocytopenia and or neutropenia.
- •More than one stenosis >50% in target vessel.
- •Lesion in aortic ostium.
- •Left main or LAD, CX lesions within 2-mm from the origin.
- •Ejection Fraction <45%.
- •STEMI in evolution.
- •Disabling stroke within previous 30 days.
- •Patients currently enrolled in another Investigational device or drug study.
- •Previous enrollment in this study.
- •Women who are currently pregnant. (A negative pregnancy test for female subjects of child bearing potential is required within 24 hours of procedure.)
- •Known or suspected active systemic infection.
- •Evidence of severe or uncontrolled systemic diseases, including chronic renal insufficiency, or any condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
研究组 & 干预措施
Mach-5 Grooved
Experimental
grooved
干预措施: coronary stent (Device)
Mach 5 Bare Metal
Experimental
bare metal
干预措施: coronary stent (Device)
结局指标
主要结局
total percentage of strut coverage by Optical Coherence Tomography analysis
时间窗: 6 month
Primary safety endpoint is the occurrence of adverse events associated with the Investigational and comparator devices.
时间窗: 6 month
late lumen loss rate by Quantative/ Qualtative Cornary Angiographia
时间窗: 6 month
binary restenosis rate by Quantative/ Qualtative Cornary Angiographia
时间窗: 6 month
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart TransplantationOutcomes ResearchExtracorporeal Membrane OxygenationHeart Transplant FailureDetermination of DeathNCT05038943University of Nebraska5
招募中
不适用
A Pilot Study With the IDEAL TM Bioabsorbable Coronary Stent Platform Eluting Sirolimus (WHISPER)Cardiovascular - Coronary heart diseaseCoronary Artery DiseaseACTRN12608000373370Bioabsorbable Therapuetics, LTD60
已完成
不适用
Evaluation of the safety and efficacy of the MHP- total hip arthroplastyhip artrosiship wear10005944NL-OMON50762Zimmer Biomet21
尚未招募
不适用
A study to assess a new endoscopy guided procedure to ameliorate acid refluxCTRI/2017/07/009182Endoscopy Research foundation
尚未招募
2 期
Effectiveness of Low carb products in mitigating blood sugar spikes in patients with Type 2 Diabetes Mellitus.CTRI/2023/05/053173Bajo Foods Pvt Ltd